Meds A-Z
Pimobendan
Detailed information about Pimobendan
Pet Owner Quick Guide
Start here: what this medicine is for, what it does, and when it's usually needed.
Usually used for:
For the delay of onset of congestive heart failure (CHF) in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD). Stage B2 preclinical MMVD refers to dogs with asymptomatic MMVD that have a moderate or l...
What it does:
Inodilator used for certain forms of canine heart failure (e.g., myxomatous mitral valve disease, dilated cardiomyopathy).
When it's needed:
Not for use in conditions where increased cardiac output is not appropriate (consult cardiology guidance).
Call your vet sooner if you notice:
- Not for use in conditions where increased cardiac output is not appropriate (consult cardiology guidance).
Commonly reported reactions:
- (2 reports)
- (2 reports)
- (2 reports)
What to ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Pimobendan
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Dog
Manufacturer: MSK
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141575 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141273 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source
Warnings / Contraindications
Not for use in conditions where increased cardiac output is not appropriate (consult cardiology guidance).
- High: Not for use in conditions where increased cardiac output is not appropriate (consult cardiology guidance).
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Most Reported Reactions
| Reaction | Cases | Species | Serious cases |
|---|---|---|---|
| 2 | Cat, Dog | 2 | |
| 2 | Cat, Dog | 2 | |
| 2 | Cat, Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 |
Species coverage: Cat (16) Dog (16)
View detailed reaction table
| Reaction | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-042089
Storage & Handling
Store at room temperature.
Documents
Official label facts are separated from secondary summaries.
Official documents: 8 • Secondary summaries: 0
- FOI Summary sN 141-575 Approved January 15, 2026.pdf · FOI
- FOI Summary oN 141-575 Approved February 13, 2024.pdf · FOI
- Vetmedin® Solution · SPL
- FOI Summary sN 141273 Approved December 19, 2025.pdf · FOI
- ucm062328.pdf · FOI
- Vetmedin® · SPL
- FOI Summary oA 200-728 Approved April 25, 2024 .pdf · FOI
- Pimomedin™ · SPL
No source yet.
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17909 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15024 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/15262/Vetmedin%C2%AE%20Solution · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17792 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/832 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/195/Vetmedin%C2%AE · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15345 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/15602/Pimomedin%E2%84%A2 · document · SPL
Promotional Materials (Marketing)
This content is marketing material and not clinical guidance.
No marketing assets are linked yet.
No source yet.
Technical appendix (vet reference)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
- Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 7:40 PM UTC
-
Animal Drugs @ FDA:
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
-
Animal Drugs @ FDA previews:
Source FDA
| Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:01 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed Feb 12, 2026, 10:41 PM UTC
Diagnosis-code mappings are not available for this medication yet.
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
- Not for use in conditions where increased cardiac output is not appropriate (consult cardiology guidance). (Contraindication, High)
Identifiers & Packages
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 0010-4131-01 | 0010 | - | |
| 0010-4479-01 | 0010 | - | |
| 0010-4480-01 | 0010 | - | |
| 0010-4481-01 | 0010 | - | |
| 0010-4482-01 | 0010 | - | |
| 0010-4610-01 | 0010 | - | |
| 0010-4612-01 | 0010 | - | |
| 13612-0034-0 | 13612 | - | |
| 13612-0034-1 | 13612 | - | |
| 46144-606-01 | 46144 | - | |
| 49452-5072-1 | 49452 | - | |
| 49452-5072-2 | 49452 | - | |
| 49452-5072-3 | 49452 | - | |
| 49452-5072-4 | 49452 | - | |
| 58597-8444-2 | 58597 | - | |
| 58597-8444-4 | 58597 | - | |
| 62157-620-01 | 62157 | - | |
| 62157-649-01 | 62157 | - | |
| 62157-654-01 | 62157 | - | |
| 62157-662-01 | 62157 | - |
Enriched Documents
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
-
FOI Summary oN 141-575 Approved February 13, 2024.pdf
• FOI summary • Official
• Feb. 2, 2026
FDA FOI summary for application 141575
-
FOI Summary sN 141-575 Approved January 15, 2026.pdf
• FOI summary • Official
• Feb. 2, 2026
FDA FOI summary for application 141575
-
ucm062328.pdf
• FOI summary • Official
• Jan. 5, 2026
FDA FOI summary for application 141273
-
FOI Summary sN 141273 Approved December 19, 2025.pdf
• FOI summary • Official
• Jan. 5, 2026
FDA FOI summary for application 141273
-
FOI Summary oA 200-728 Approved April 25, 2024 .pdf
• FOI summary • Official
• May 1, 2024
FDA FOI summary for application 200728
Data Sources & Revision History
Every non-trivial field is expected to include provenance and update timestamps.
- overdose_info: Overdose may lead to severe tachycardia, hypotension, arrhythmias, or collapse. Supportive and critical care is recommended. (Clinical, 2026-02-12)
- storage_handling: Store at room temperature. (Clinical, 2026-02-12)
- contraindications: Not for use in conditions where increased cardiac output is not appropriate (consult cardiology guidance). (Official, 2026-02-12)
- side_effects: GI upset, increased heart rate, lethargy. (Official, 2026-02-12)
- usage: Inodilator used for certain forms of canine heart failure (e.g., myxomatous mitral valve disease, dilated cardiomyopathy). (Official, 2026-02-12)
- side_effects updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
- contraindications updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
- usage updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
FDA Products & Applications (Animal Drugs @ FDA)
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
Vetmedin® Solution
RX
Pimobendan
Solution
• Oral
|
Boehringer lngelheim Animal Health USA, Inc. | NADA 141-575 | Approved | Feb 2, 2026 |
|
Vetmedin®
RX
Pimobendan
Tablet (Chewable)
• Oral
|
Boehringer lngelheim Animal Health USA, Inc. | NADA 141-273 | Approved | Jan 5, 2026 |
|
Pimomedin™
RX
Pimobendan
Chewable Tablets
• Oral
|
Cronus Pharma Specialities India Private Ltd. | ANADA 200-728 | Approved | May 1, 2024 |
Data source: FDA Animal Drugs @ FDA (public search export).
What It's For (FDA Label Highlights)
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
Composition / specifications
For the delay of onset of congestive heart failure (CHF) in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD). Stage B2 preclinical MMVD refers to dogs with asymptomatic MMVD that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly.
For the management of the signs of mild, moderate, or severe CHF in dogs due to clinical MMVD or dilated cardiomyopathy (DCM). For use with concurrent therapy for CHF (e.g., furosemide, etc.) as appropriate on a case-by-case basis.
Administer orally at a total daily dose of 0.23 mg/lb (0.5 mg/kg) body weight. The total daily dose should be divided into 2 equal portions administered approximately 12 hours apart (i.e., morning and evening).
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
Vetmedin® is indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease. Stage B2 preclinical myxomatous mitral valve disease (MMVD) refers to dogs with asymptomatic MMVD that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly.
For the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical MMVD or dilated cardiomyopathy (DCM); for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.
Administer orally at a total daily dose of 0.23 mg/lb. (0.5 mg/kg) body weight, using a suitable combination of whole or half tablets. The total daily dose should be divided into 2 portions that are not necessarily equal, and the portions should be administered approximately 12 hours apart (i.e., morning and evening). The tablets are scored, and the calculated dosage should be provided to the nearest half tablet increment.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM); for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.
Administer orally at a total daily dose of 0.23 mg/lb (0.5 mg/kg) body weight, using a suitable combination of whole or half tablets. The total daily dose should be divided into 2 portions that are not necessarily equal, and the portions should be administered approximately 12 hours apart (i.e., morning and evening).
FDA page: Open in Animal Drugs @ FDA
Official Documents (FDA)
Direct links to FDA-hosted PDFs and SPL packages (when available).
-
Summary
This supplement provides for the addition of the indication for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD). Stage B2 preclinical MMVD refers to dogs with asymptomatic MMVD that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly.
-
Summary
For the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM); for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.
- Vetmedin® Solution (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
This supplement provides for the addition of the indication for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease. Stage B2 preclinical myxomatous mitral valve disease (MMVD) refers to dogs with asymptomatic MMVD that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly.
-
FOI ucm062328.pdf
Summary
VETMEDIN (pimobendan) is indicated for the management of the signs of mild, moderate, or severe (modified NYHA Class IIa, IIIb, or IVc) congestive heart failure in dogs due to atrioventricular valvular insufficiency (AVVI) or dilated cardiomyopathy (DCM). VETMEDIN is indicated for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis. a A dog with modified New York Heart Association (NYHA) Class II heart failure has fatigue, shortness of breath, coughing, etc. apparent when ordinary exercise is exceeded.
b A dog with modified NYHA Class III heart failure is comfortable at rest, but exercise capacity is minimal.
c A dog with modified NYHA Class IV heart failure has no capacity for exercise and disabling clinical signs are present even at rest.
- Vetmedin® (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM); for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.
- Pimomedin™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
Usage
Inodilator used for certain forms of canine heart failure (e.g., myxomatous mitral valve disease, dilated cardiomyopathy).
Source: FDA Animal Drugs @ FDA • Reference
Contraindications
Not for use in conditions where increased cardiac output is not appropriate (consult cardiology guidance).
Side Effects
GI upset, increased heart rate, lethargy.
Source: FDA openFDA • Reference
Top Reported Reactions (openFDA)
Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Chihuahua, Female, 16 year, 3.12 kilogram • Drug: MSK, Unknown • Reactions: Reduced responses, Elevated creatinine, Corneal ulcer, Sleepiness - systemic disorder, Elevated blood urea nitrogen… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-055817
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Female
- Age: 16.00 Year
- Weight: 3.120 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
Dog, Chihuahua, Female, 12.2 year, 3.901 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Vomiting, Underdose, Hypothermia, Unsteady walking (ataxia), Dehydration… • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-054506
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Female
- Age: 12.20 Year
- Weight: 3.901 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Unassigned
Dog, ['Dachshund (unspecified)', 'Chihuahua'], Female, 15 year, 5.171 kilogram • Drug: MSK, Solution, Unknown • Reactions: Vomiting • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-056158
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 15.00 Year
- Weight: 5.171 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Solution
Dog, Spaniel - King Charles Cavalier, Female, 11 year, 10.795 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 0.23 Milligram per kilogram, Frequency: 12 per hour • Reactions: Cough, Tachypnoea, Found dead • Outcome: Died
- Report ID: USA-USFDACVM-2025-US-055870
- Serious AE: Yes
- Treated For AE: No
- Sex: Female
- Age: 11.00 Year
- Weight: 10.795 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 0.23 Milligram per kilogram
- Frequency: 12 per hour
Dog, Dog (unknown), Unknown, 16 year • Drug: MSK, Tablet, chewable, Oral, Frequency: 1 per day • Reactions: Loose stool • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-055593
- Serious AE: No
- Treated For AE: Yes
- Sex: Unknown
- Age: 16.00 Year
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Frequency: 1 per day
Dog, Dachshund (unspecified), Female, 14.5 year, 8.618 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Head tremor, Overdose • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-053701
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 14.50 Year
- Weight: 8.618 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Unassigned
Cat, Domestic Shorthair, Female, 11 year, 7.893 kilogram • Drug: MSK, Solution, Oral, Dose: 0.25 Milligram per kilogram, Frequency: 12 per hour • Reactions: Loss of appetite • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-055587
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 11.00 Year
- Weight: 7.893 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Solution
- Dose: 0.25 Milligram per kilogram
- Frequency: 12 per hour
Cat, Cat (unknown), Unknown • Drug: MSK, Tablet, chewable, Unknown • Reactions: Agitation, Palpitation • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-042089
- Serious AE: No
- Treated For AE: No
- Sex: Unknown
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Unknown
- Form: Tablet, chewable
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
Overdose may lead to severe tachycardia, hypotension, arrhythmias, or collapse. Supportive and critical care is recommended.
Storage & Handling
Store at room temperature.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.